Abstract. Sphingosine-1-phosphate (SIP) serves an important role in various physiological and pathophysiological processes, including the regulation of cell apoptosis, proliferation and survival. Sphingosine kinase 1 (SPHK1) is a lipid kinase that phosphorylates sphingosine to generate SIP. SIP has been proven to be positively correlated with chemotherapy resistance in breast cancer, colorectal carcinoma and non-small cell lung cancer. However, whether SPHK1 is involved in the development of cisplatin resistance remains to be elucidated. The present study aimed to identify the association between SPHK1 and chemoresistance in bladder cancer cells and to explore the therapeutic implications in patients with bladder cancer. Bladder cancer cell proliferation and apoptosis were determined using Cell Counting Kit-8 assays and flow cytometry, respectively. Apoptosis-related proteins were detected via western blotting. The results revealed that SPHK1 was positively correlated with cisplatin resistance in bladder cancer cells, exhibiting an antiapoptotic effect that was reflected by the downregulation of apoptosis-related proteins (Bax and cleaved caspase-3) and the upregulation of an antiapoptotic protein (Bcl-2) in SPHK1-overexpression cell lines. Suppression of SPHK1 by small interfering RNA or FTY-720 significantly reversed the antiapoptotic effect. A potential mechanism underlying SPHK1-induced cisplatin resistance and apoptosis inhibition may be activation of STAT3 via binding non-POU domain containing octamer binding. In conclusion, the present study suggested that SPHK1 displayed significant antiapoptotic effects in cisplatin-based treatment, thus may serve as a potential novel therapeutic target for the treatment for bladder cancer.

Introduction

As one of the most prevalent malignant tumor types worldwide, bladder cancer exhibited the fifth highest incidence rate among new confirmed cases of cancer in men in the USA and the estimated death toll reached 13,050, accounting for 4% of total cancer-related deaths in 2020. According to the European Association of Urology guidelines, the therapeutic options for bladder cancer include radical surgery, neo-adjuvant therapy and traditional chemotherapy. The high drug resistance to traditional chemotherapy is a challenge for the treatment of bladder cancer. Although neo-chemotherapy based on cisplatin was considered promising, 40% of patients experienced therapeutic failure due to acquired chemoresistance. Therefore, exploring the mechanism underlying the development of cisplatin resistance in bladder cancer cells is important for the optimization of therapeutic strategies.

Sphingosine kinase 1 (SPHK1), which phosphorylates sphingosine to generate sphingosine-1-phosphate (SIP) (5), has been demonstrated to exert various functions at different stages of cancer progression. For instance, SPHK1 overexpression contributes to drug resistant to oxaliplatin in the human colon cancer RKO cell line, whereas SPHK1 downregulation increases drug sensitivity to oxaliplatin in the human colon cancer HCT116 cell line. A number of studies have reported that SPHK1 could affect the chemoresistance of colorectal cancer by regulating STAT3 expression, influencing tumorigenesis, proliferation and progression. However, the effect of SPHK1 in promoting cisplatin resistance in bladder cancer cells is not completely understood.

The present study demonstrated that that SPHK1 inhibited apoptosis and promoted cisplatin resistance by forming a complex with the RNA binding protein non-POU domain containing octamer binding (NONO) in bladder cancer cells. Furthermore, NONO modulated STAT3 activity and displayed a negative association with cisplatin responsiveness. The identification of the SPHK1/NONO/STAT3 axis may provide promising insight into the biological characteristics of bladder cancer cells and aid with the identification of alternative therapeutic strategies.

Correspondence to: Professor Weiyang He, Department of Urology, The First Affiliated Hospital of Chongqing Medical University, 1 Youyi Road, Yuzhong, Chongqing 400016, P.R. China

E-mail: weiyang361@aliyun.com

*Contributed equally

Key words: cisplatin resistance, bladder cancer, sphingosine kinase 1, apoptosis, non-POU domain containing octamer binding, STAT3
Statistics acquisition. A total of 411 transcriptome profiling files from 430 samples were extracted from The Cancer Genome Atlas (TCGA; https://portal.gdc.cancer.gov/) Genomic Data Commons. Subsequently, two gene sets of chemotherapy-resistant bladder cancer cell lines [GSE7883 (12) and GSE58624 (13)] and four gene sets of cisplatin-resistant cancer types [GSE58624/bladder, GSE108214/lung (14), GSE140996/ovarian (15) and GSE77515/breast (16)] were obtained from the Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo) of National Center for Biotechnology Information. The identification of differentially expressed genes (DEGs) was performed by GEO2R (https://www.ncbi.nlm.nih.gov/geo). The cut-off criteria. The Venn diagram reflecting the differentially expressed genes was acquired using bio-Venn software (https://www.biovenn.nl/). The Kaplan-Meier survival curve analysis was performed using Gene Expression Profiling Interactive Analysis (http://gepia.cancer-pku.cn/). The cut-off/threshold value was Quartile: Cutoff-High (75%); Cutoff-Low (25%).

Patients and tissue samples. Bladder cancer and adjacent healthy tissue samples were obtained from 10 patients admitted to the First Affiliated Hospital of Chongqing Medical University (Chongqing, China; Table I) between April 2020 and January 2021. The fresh samples were washed with PBS and then stored at -80˚C prior to RNA extraction. Written informed consent was obtained from patients. The present study was approved by Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (ethical approval no. 2021086).

Cell lines and chemical reagents. Human bladder cancer cell lines (T24, UMUC-3 and 5637) and normal urothelial cells (SV-HUC-1) were purchased from the American Type Culture Collection. Cells were cultured in RPMI-1640 (Corning, Inc.; for T24 and 5637 cells), DMEM (Gibco; Thermo Fisher Scientific, Inc.; for UMUC-3 cells) containing 10% FBS (Gibco; Thermo Fisher Scientific, Inc.; for UMUC-3 cells) or F-12K (for SV-HUC-1 cells; Gibco; Thermo Fisher Scientific, Inc.; 94˚C 2 min, one cycle; 94˚C 40 sec, 50˚C 40 sec, 72˚C 1 min for 35 cycles and 72˚C for 5 min and one cycle). Relative mRNA expression levels were quantified using the DeltaDelta Ct method (17) and normalized to the internal reference gene GAPDH. The following primers were used for qPCR: SPHK1 forward, 5'‑GcG UcA UGc AUc UGU UcU ATT ‑3'; reverse, 5'‑UcA CcU UGU GcU cAc GC‑3'. The experiments were replicated three times.

Small interfering RNA (siRNA) and lentivirus transfection. All small interfering RNAs (siRNAs) targeting human SPHK1 (siRNA1, siRNA2, siRNA3) and the scrambled negative control (NC) were designed and synthesized by Shanghai GenePharma Co., Ltd. For siRNA transfection, T24 and UMUC-3 cells were cultured in 6-well plates (5x10⁵ cells/well). At 80% confluence, the culture media was replaced with 1.5 ml basal medium containing 500 ml Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) and 0.2 nmol siRNA. The sequences of the siRNAs were as follows: si-SHK1-1#: 5'‑GcAGcGcACGACUGcAUGcG‑3'; si-SHK1-2#: 5'‑GcGcUcAUGcUcAUGcGUcUG‑3'; si-SHK1-3#: 5'‑GcGcACUGcAUGcGUcUG‑3'; si-SHK1-4#: 5'‑GcGcACUGcAUGcGUcUG‑3'. To create cell lines overexpressing SPHK1 or a control vector, a lentiviral system from Shanghai GenePharma Co., Ltd. was used. Empty vector was used as a negative control. For lentivirus transduction, at 50% confluence, medium containing lentivirus and polybrominated biphenyls was added to T24 cells at a multiplicity of infection of 50, according to the manufacturer's protocol. Polybrene was used to improve the infection efficiency. The transfection temperature was 37˚C for 24 h. At 24 h post-transfection, the supernatant was replaced with RPMI-1640, followed by culture for a further 24 h at 37˚C. Puromycin (2 ng/ml) was added to the medium for stable selection of transfected cell lines.

RNA extraction and reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted from bladder cancer and adjacent healthy tissue samples, as well as cell lines (at 70% confluence) using TRIzol® reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Total RNA (1 µg) was reverse transcribed into cDNA using the PrimeScript RT reagent kit (Takara Bio, Inc.) according to the manufacturer's instructions. qPCR was performed using SYBR Green assays (Takara Bio, Inc.) and an ABI 7500 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.; 94˚C 2 min, one cycle; 94˚C 40 sec, 50˚C 40 sec, 72˚C 1 min for 35 cycles and 72˚C for 5 min and one cycle). Relative mRNA expression levels were quantified using the 2^−ΔΔCt method and normalized to the internal reference gene GAPDH.

Flow cytometry. siRNA-transfected UMUC-3 and T24 cells were seeded into 6-well plates and incubated with cisplatin (0, 5 or 10 µg/ml) for 48 h. After washing twice with PBS, cells (~1x10⁶ cells/plate) were resuspended in 500 ml PBS. Cells were transferred to 1.5 ml Eppendorf tubes and stained using the FITC Annexin V Apoptosis Detection Kit II (BD Biosciences, cat. no. 556570) and incubated in the dark for 10 min at room temperature according to the manufacturer's protocol. Subsequently, 10 µl propidium iodide (PI, Beyotime Institute of Biotechnology) was added to the stained cells and apoptotic cells were distinguished by a fluorescence-activated cell sorting analyzer (FACS; BD Biosciences).
Table I. Patient information.

| ID       | Age | Sex | Grade | T stage | N stage | M stage | Start   | End       |
|----------|-----|-----|-------|---------|---------|---------|---------|-----------|
| 1999981  | 78  | Male| Unknown | T1      | N1      | Unknown | 20.06.10 | 20.06.16  |
| 2023999  | 58  | Male| High   | T1      | N1      | M0      | 20.04.05 | 20.04.16  |
| 1903064  | 63  | Female| High   | T4      | N0      | M0      | 21.02.06 | 21.02.15  |
| 2030137  | 56  | Male| High   | T2a     | N0      | M0      | 20.09.16 | 20.09.29  |
| 2002228  | 74  | Male| Low    | T2b     | N0      | M0      | 20.10.11 | 20.10.20  |
| 2004550  | 73  | Male| High   | T3      | N2      | M0      | 21.01.15 | 21.01.24  |
| 2006935  | 74  | Male| High   | T4      | N2      | M0      | 21.01.15 | 21.01.26  |
| 2025171  | 65  | Male| High   | T1      | N0      | M0      | 20.06.30 | 20.07.10  |
| 1984663  | 64  | Male| High   | T1      | N0      | M0      | 20.08.31 | 20.09.08  |
| 1990615  | 51  | Male| High   | T3b     | N0      | M0      | 20.07.15 | 20.07.23  |

analyzed by Cytexpert V2.3 (Beckman Coulter, Inc.) software. The apoptotic rate was calculated by the percentage of early + late apoptotic cells.

**Western blotting.** Proteins were extracted from cell lines using RIPA lysis buffer (Beyotime Institute of Biotechnology) containing 50 mmol/l Tris-HCl (pH 7.4), 150 mmol/l NaCl, 1% Triton X-100, 1 mmol/l EDTA (pH 8.0) and 1 mmol/l phenylmethylsulfonyl fluoride. Total protein concentrations were measured using the BCA quantitative kit (Beyotime Institute of Biotechnology). Proteins (30 μg) were separated via 12% SDS-PAGE and transferred to PVDF membranes. After blocking with 5% skimmed milk for 2 h at room temperature, the membranes were incubated overnight at 4°C with the following primary antibodies: SPHK1 (cat. no. 10670-1-AP; ProteinTech Group, Inc.; 1:1,000), GAPDH (cat. no. AB0037; Shanghai Abways Biotechnology Co., Ltd.; 1:5,000), NONO (cat. no. 385171; ZenBio, Inc.; 1:1,000), phosphorylated (p)-STAT3 (cat. no. 380906; ZenBio, Inc.; 1:1,000), Bax (cat. no. 50599-2-Ig; Cell Signaling Technology, Inc.; 1:1,000), BAD (cat. no. 13621-1-AP; ProteinTech Group, Inc.; 1:1,000), Bcl-2 (cat. no. 12789-1-AP; Cell Signaling Technology, Inc.; 1:1,000), caspase-3 (cat. no. 9661; Cell Signaling Technology, Inc.; 1:1,000). After washing three times with TBS-Tween (0.1%) and 20 (TBST), the membranes were semi-quantified using Quantity One software (v4.4.0.36; Bio-Rad Laboratories, Inc.). Protein A/G beads were added to each sample, followed by rotation at 4°C overnight with a rolling incubator (cat. no. QB-128; Kylin-Bell Instruments Co., Ltd.). Protein A/G beads were added to the cell lysate and then rotated for 7 h at 4°C. The beads were washed three times with IP buffer on a magnetic shelf and subsequently, 2.5 μg SPHK1 and IgG primary antibody were incubated with HRP-conjugated secondary antibodies and protein A/G beads were added to each sample, followed by rotation at 4°C overnight with a rolling incubator (cat. no. QB-128; Kylin-Bell Instruments Co., Ltd.). Protein A/G beads were added to the cell lysate and then rotated for 7 h at 4°C. The beads were washed three times with IP buffer on a magnetic shelf and then boiled in 2X SDS loading buffer for 10 min. For mass spectrometry experiments, SPHK1-overexpression T24 cells were harvested and lysed at 4°C. Subsequently, the IP experiment was performed as aforementioned. Tubes containing beads were sent to Trump Biotechnology Co., Ltd. for mass spectrometry and further analysis.

**Statistical analysis.** Data were expressed as the mean ± standard deviation. GraphPad Prism 8 software (GraphPad Software, Inc.) and SPSS 22.0 (IBM Corp.) were used for statistical analyses. For statistical comparisons, a paired t-test was used when comparing matched samples and an unpaired t-test for non-matched samples. Dunnett test was the post hoc test used following two-way ANOVA for multiple comparisons. For the Kaplan-Meier survival curve analysis, log-rank was used to compare the curves. P<0.05 was considered to indicate a statistically significant difference. Figures were produced using Adobe Photoshop CC 2018 (Adobe Systems, Inc.).

**Results**

**Identifying the target gene SPHK1.** The gene sets related to chemoresistance in patients with bladder cancer were demonstrated by the gene sets obtained from the GEO database (Fig. 1A and B). The Venn diagram revealed two cross-linked genes among the 885 upregulated genes in the GSE77883 gene set and 36 upregulated genes in the GSE58624 gene set (Fig. 1C). There were six cross-link genes among the four gene sets of selected cisplatin-resistant cancer types (Fig. 1D). Comprehensive analysis of the results demonstrated that SPHK1 was the only gene contained in both cohorts. Therefore, SPHK1 was selected as the target gene in the present study.

**SPHK1 is associated with the prognosis of patients with bladder cancer.** A higher expression level of SPHK1 was observed in bladder cancer tissues compared with those in healthy adjacent tissues both in the 19 paired samples (P=0.00; Fig. 2A) and TCGA database of 430 clinical samples (P=0.016; Fig. 2B). Kaplan-Meier curves revealed that patients in the high expression SPHK1 group displayed a notably lower overall survival rate compared with those in the low expression group in GEPIA database (Fig. 2C). Immunohistochemical staining images from the Human Protein Atlas database (https://www.proteinatlas.org/) showed that SPHK1 intensity in bladder...
cancer tissues was stronger compared with that in adjacent mucosa (Fig. 2D). The RT-qPCR results demonstrated that the higher gene expression of SPHK1 was not only observed in all three bladder cancer cell lines, including T24, 5637 and UMUC-3 (Fig. 2E), but also in the tumor tissues of extracted patients samples (Fig. 2F). Collectively, the results suggested
that SPHK1 was upregulated in bladder cancer and was significantly correlated with the prognosis of patients.

**SHPK1 knockdown increases cisplatin sensitivity and promoted the proliferation of bladder cancer cell lines.** The role of SPHK1 in the development of cisplatin resistance in bladder cancer cells was investigated. In T24 and UMUC-3 cell lines, SPHK1 knockdown (Fig. 3A and B) led to increased sensitivity to cisplatin treatment compared with the negative control (Fig. 3C and D). At a concentration of 1 µg/ml, the two bladder cancer cells were most sensitive to cisplatin treatment (P<0.001). In addition, the flow cytometry results demonstrated that SPHK1 knockdown displayed a higher rate of apoptosis compared with the negative control (Fig. 3E and F). The results demonstrated that SPHK1 knockdown promoted cell proliferation, increased cisplatin sensitivity and induced apoptosis in bladder cancer cells.
Figure 3. SPHK1 knockdown increases cisplatin sensitivity in bladder cancer cell lines. SPHK1 expression levels in transfected T24 cells were determined by (A) PCR ("**P<0.01 SiRNA2 vs. NC") and (B) western blotting ("**P<0.01 Si2 vs. NC"). Cell proliferation was detected in (C) T24-Si vs. NC (0.5 µg/ml: "**P<0.01 Si2 vs. NC, and 1 µg/ml: "**P<0.01 Si2 vs. NC) and (D) UMUC-3-Si vs. NC (0.2 µg/ml: "**P<0.01 Si2 vs. NC, 0.5 µg/ml: "**P<0.01 Si2 vs. NC, 1 µg/ml: "**P<0.01 Si2 vs. NC) by performing Cell Counting Kit-8 assays. Apoptosis was analyzed in (E) T24-Si vs. NC (1 µg/ml: "**P<0.01 Si2 vs. NC, 2 µg/ml: "**P<0.01 Si2 vs. NC) and (F) UMUC-3-Si vs. NC (1 µg/ml: "**P<0.01 Si2 vs. NC, 2 µg/ml: "**P<0.01 Si2 vs. NC) via flow cytometry. SPHK1, sphingosine kinase 1; si, small interfering; NC, negative control.
SPHK1 overexpression decreases apoptosis in T24 bladder cancer cells. First, SPHK1-overexpression cell lines were constructed by lentivirus transduction (Fig. 4A). The RT-qPCR and western blotting results showed that the expression level of SPHK1 was significantly increased after viral transduction (Fig. 4B and C). The CCK-8 assay results displayed that SPHK1 overexpression significantly promoted cell proliferation (Fig. 4D). Flow cytometry results showed that SPHK1 overexpression also decreased the apoptotic rate (Fig. 4E). The expression of apoptosis-related proteins, including Bcl-2, Bax and cleaved caspase-3, were detected using western blotting. In SPHK1-overexpression cell lines, Bcl-2 was significantly
downregulated, whereas Bax and cleaved caspase-3 were upregulated. Compared with normal T24 cells, SPHK1-overexpression T24 cell lines exhibited higher expression levels of Bcl-2 and lower expression levels of Bax and cleaved caspase-3 following treatment with cisplatin (Fig. 4F). The aforementioned results demonstrated that SPHK1 overexpression contributed to cisplatin resistance and decreased apoptosis in bladder cancer cells.

**SPHK1 regulates STAT3 expression via binding to NONO.** Co-IP was performed to explore the mechanism underlying SPHK1-mediated regulation of apoptosis in bladder cancer cells (Fig. 5A). Based on the mass spectrometry results, a novel protein, NONO, was identified (Fig. 5B). The western blotting results showed that SPHK1-overexpression cell lines displayed higher expression levels of NONO and its downstream signaling molecule p-STAT3 compared with those in normal T24 cells (Fig. 5C).

**SPHK1 inhibition reverses antiapoptotic effects in bladder cancer cells.** Our previous results demonstrated that SPHK1 is responsible for cisplatin resistance in bladder cancer cells. Numerous studies have demonstrated that FTY-720 is an inhibitor of SPHK1 (18,19) and may induce apoptosis in bladder cancer cells (20). Hence, whether inhibition of SPHK1 by FTY-720 could reverse antiapoptotic effects and increase cisplatin sensitivity in bladder cancer cells was investigated. The western blotting results demonstrated that there was a significant decrease in SPHK1 expression after FTY-720 administration (Fig. 6A). In addition, SPHK1 knockdown led to decreases in NONO and STAT3 expression (Fig. 6B), suggesting that NONO may serve as a downstream regulator of SPHK1. Furthermore, the expression levels of the apoptosis-related proteins Bax and cleaved caspase-3 were increased, whereas Bcl-2 expression levels were decreased after SPHK1 inhibition (Fig. 6C), indicating that SPHK1-induced antiapoptotic effects were dependent on NONO-regulated STAT3 activation.

**Discussion**

Tumor progression is regulated by various mechanisms (21-23). The present study demonstrated that SPHK1 overexpression was significantly associated with the development of chemoresistance in bladder cancer cells. Elevated SPHK1 enhanced the
chemoresistance to cisplatin and contributed to poor survival rates in patients with bladder cancer. The chemoresistance to cisplatin was reversed by SPHK1 knockdown via siRNA transfection or FTY-720 treatment.

SPHK1 is reported to influence the biological behaviors of cancer cells, including angiogenesis, cell proliferation and motility, survival, autophagy and apoptosis (9). Mediating apoptosis via suppression of ceramide (24) might be one of the most important oncological implications for overcoming chemoresistance in various cancer cells, leading to an improved prognosis of patients. SPHK1 can induce chemoresistance and inhibit apoptosis in numerous types of cancer, such as acute myeloid leukemia (25), chronic myeloid leukemia (26) and breast cancer (27) and is regarded as a potential sensor to chemotherapy in prostate cancer (28). However, the role of SPHK1 in regulating cisplatin-induced apoptosis in bladder cancer remains to be elucidated. To the best of the authors' knowledge, the present study demonstrated for the first time that SPHK1 inhibition increased the expression of Bax and cleaved caspase-3, but downregulated the expression of the antiapoptotic protein Bcl-2. The CCK-8 assay results demonstrated that SPHK1 was positively associated with bladder cancer cell proliferation. SPHK1-overexpression T24 cells displayed a lower sensitivity to cisplatin treatment. In addition, the present study indicated that inhibition of SPHK1 by FTY-720 enhanced the apoptotic effect of cisplatin treatment in bladder cancer cells.

RNA binding proteins (RBPs) have recently emerged as critical factors that regulate multiple cellular activities, including pre-mRNA splicing, translation and protein sub-cellular localization (29,30). NONO is a novel RBP that is located in the nucleus of numerous mammalian cells and distributed in the sub-nuclear domain and participates in almost every step of gene regulation (31). Studies have found that NONO

Figure 6. SPHK1 inhibition reverses the antiapoptotic effect in bladder cancer cells. (A) Inhibition efficiency of SPHK1 inhibitor FTY-720 as determined via western blotting (**P<0.001). (B) Inhibition of SPHK1 decreased the expression of NONO and p-STAT3 (**P<0.001). (C) Inhibition of SPHK1 decreased apoptosis in bladder cancer cells (**P<0.001). SPHK1, sphingosine kinase 1; NONO, non-POU domain containing octamer binding; p-, phosphorylated; OE, overexpression.
Figure 7. Validation of SPHK1 and its corresponding proteins in the T24/DDP cell line. (A) DPP-resistant T24 bladder cancer cells were established and drug resistance was detected by performing the CCK-8 assay (1 µg/ml: ***P<0.001 T24/DDP vs. T24; 2 µg/ml: ***P<0.001 T24/DDP vs. T24). (B) Apoptosis was analyzed in T24 vs. T24/DDP (1 µg/ml: ***P<0.001 T24/DDP vs. T24; 2 µg/ml: ***P<0.001 T24/DDP vs. T24). (C and D) SPHK1, NONO and p-STAT3 were overexpressed in the T24/DDP cell line (***P<0.001). Following SPHK1 knockdown in the T24/DDP cell line, the results of (E and F) western blotting, (G) flow cytometry and (H) CCK-8 assay were similar to those reported in previous studies (*P<0.05, **P<0.01 and ***P<0.001). SPHK1, sphingosine kinase 1; DPP, cisplatin; CCK-8, Cell Counting Kit-8; NONO, non-POU domain containing octamer binding; p-, phosphorylated; OE, overexpression.
also serves an important role in tumorigenesis, including proliferation regulation, DNA damage repair, cell migration and apoptosis (32). For example, silencing NONO can inhibit cell attachment to laminin, poly-L-lysine11 and the surface of culture plates, thus reducing cell migration in melanoma (32) and esophageal cancer (33). Notably, NONO is found to inhibit tumor metastasis in bladder cancer cells (34). Liang et al (35) identified that NONO directly interacted with splicing factor proline/glutamine rich to regulate the splicing of SET domain and mariner transposase fusion gene, thus suppressing the invasion of bladder cancer cells. NONO is also found to promote apoptosis by activating caspase-3 and Bax proteins (36), which is consistent with the results of the present study. In addition, the IP results further indicated that NONO may serve as a pivotal regulator of SPHK1-induced cisplatin resistance and SPHK1 could bind to NONO to inhibit cisplatin-induced apoptosis.

Although the antiapoptotic effect of SPHK1 on bladder cancer cells has been confirmed, the specific mechanism remains unclear. It has been previously reported that SPHK1 phosphorylates sphingosine to generate S1P to activate STAT3 (37). The mechanisms underlying STAT3-mediated induction of cisplatin resistance are complex, including reducing uptake (38-40), cisplatin inactivation (41,42) and most importantly, increasing DNA damage repair (43). It has been reported that cisplatin can form inter- and intrastand crosslinked DNA adducts in cells and activate the proapoptotic protein P73 (44) and the accumulation of P37 could result in the release of cytochrome c and ultimately lead to cell apoptosis (45,46). DNA mismatch repair (MMR) is a process that corrects mismatched nucleotides by the recognition of inter- and intrastand DNA adducts and the consequent release of an apoptotic signal. MMR is often impaired in cisplatin-resistant cancer cells (47). MMR deficiency usually results in downregulation of MutS homolog 3 (MSH3), which is associated with cisplatin sensitivity and patient survival (47). Notably, STAT3 activation regulates MSH3 expression in colorectal cancer cells (48). The present study demonstrated that upregulation of p-STAT3 led to increased apoptosis in bladder cancer cells and thus it was suggested that one of the mechanisms underlying SPHK1-induced cisplatin resistance might be regulation of STAT3 expression to activate the downstream signature and inhibit the MMR pathway; however, further investigations are required.

Furthermore, DNA damaged-induced cisplatin resistance can also be reversed by homologous recombination (HR), a non-STAT3-dependent pathway that repairs the doublestrand breaks (49). Since the HR pathway has been found to serve a role in platinum-based therapy resistance of breast cancer, HR was inhibited by NONO in vivo (50) and the present study demonstrated that SPHK1 could regulate the expression of NONO and it was indicated that SPHK1 might induce cisplatin resistance through the STAT3-dependent pathway, as well as the non-STAT3-dependent HR pathway.

The present study had a number of limitations. First, the lack of in vivo experiments may affect the credibility of the present study. Second, although the present study confirmed the existence of SPHK1/NONO/STAT3 axis, the mechanisms underlying DNA double strands repair are still unclear and require further research.

To the best of the authors' knowledge, the present study demonstrated for the first time that SPHK1 may promote cisplatin resistance and inhibit apoptosis in bladder cancer cells. The antiapoptotic effect of SPHK1 was exerted via binding with the DNA regulating protein NONO. In addition, the combination of SPHK1 and NONO may activate STAT3 to promote the survival of bladder cancer cells.

Acknowledgements

The authors thank the Laboratory Research Center, The First Affiliated Hospital of Chongqing Medical University (Chongqing, China) for technical support.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81874092).

Availability of data and materials

The datasets generated and/or analyzed during the current study are available at TCGA dataset (https://portal.gdc.cancer.gov/) and GEO datasets https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58624; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE108214; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140996; and https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77515.

Authors' contributions

HT and WH conceived the study. HT and ZQ collected the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (Ethical approval number: 2021086-Ethics Committee of the First Affiliated Hospital of Chongqing Medical University; 3 March 2021).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin 70: 7-30, 2020.
2. Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, Hernández V, Linares Espinós E, Lorch A, Neuzillet Y, et al: European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines. Eur Urol 79: 82-104, 2021.
17. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)) method. Methods 25: 402-408, 2001.

18. Lu J, Zhou D, Lei L, Zhang K and Lei H: TET2 expression and its regulatory role in gastric cancer treatment. Int J Surg Oncol 2012: 862879, 2012.

19. Luiwiler A and Zangemeister-Wittke U: The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Towards a systems pharmacology approach. Int J Mol Sci 19: 767, 2018.

20. Lu L, Wang L, Li X, Liu J, Zhao Z, Chen Z, He A, Jiang Y, Song L, Wu X and He Y: Identification of distinct NonO and tumorigenesis: More than a biomarker. Int J Biochem Cell Biol 58: 61-69, 2014.

21. Lu X, Zhao X, Li Y, Liu Y, Zhang F, et al: The potential of BIN1 to Act as a potent predictor of cisplatin sensitivity in gastric cancer treatment. Int J Surg Oncol 2012: 862879, 2012.

22. Lu X, Zhao X, Li Y, Liu Y, Zhang F, et al: The potential of BIN1 to Act as a potent predictor of cisplatin sensitivity in gastric cancer treatment. Int J Surg Oncol 2012: 862879, 2012.

23. Ibáñez P, Ballesteros J, Ballesteros A, et al: Oligonucleotide treatment of in vivo glioblastoma: A proof of concept. Biochem Pharmacol 83: 212-219, 2012.

24. Ibarra J, Gómez-Herrero E, et al: The potential of BIN1 to Act as a potent predictor of cisplatin sensitivity in gastric cancer treatment. Int J Surg Oncol 2012: 862879, 2012.
44. Viktorsson K, Ekedahl J, Lindebro MC, Lewensohn R, Zhivotovsky B, Linder S and Shoshan MC: Defective stress kinase and Bak activation in response to ionizing radiation but not cisplatin in a non-small cell lung carcinoma cell line. Exp Cell Res 289: 256-264, 2003.
45. Adams JM: Ways of dying: Multiple pathways to apoptosis. Genes Dev 17: 2481-2495, 2003.
46. Kanke TA and Erie DA: DNA mismatch repair. Annu Rev Biochem 74: 681-710, 2005.
47. Vaismen A, Varchenko M, Umar A, Kunkel TA, Risinger JJ, Barrett JC, Hamilton TC and Chaney SG: The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58: 3579-3585, 1998.
48. Tseng-Rogenski SS, Hamaya Y, Choi YD and Carethers JM: Interleukin 6 alters localization of hMSH3, leading to DNA mismatch repair defects in colorectal cancer cells. Gastroenterology 148: 579-589, 2015.
49. Rocha C, Silva MM, Quinet A, Cabral-Neto JB and Menck C: DNA repair pathways and cisplatin resistance: An intimate relationship. Clinics (Sao Paulo) 73 (Suppl 1): e478s, 2018.
50. Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardt AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, et al: Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci USA 110: 17041-17046, 2013.